Embed this press release by copying the code below:
Actinium Receives Orphan-Drug Designation from FDA for Actimab-a in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Actinium Receives Orphan-Drug Designation from FDA for Actimab-a in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients